What's new in mechanical treatment of acute renal failure?;Was gibt's neues in der mechanischen therapie des akuten nierenversagens?

Intensiv- und Notfallbehandlung

Volumn 34, Issue 2, 2009, Pages 94-103

  Hilge, R ^a   Fischereder, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute renal failure; Argatroban; Artificial kidney; Citrate; Contrast agent induced renal failure; CVVHF; Dialysis; Dialysis dose; High cut off filter; Renal replacement therapy

Indexed keywords

ARGATROBAN; CITRIC ACID; CONTRAST MEDIUM; HEPARIN; NADROPARIN;

ACUTE KIDNEY FAILURE; ANGIOCARDIOGRAPHY; ARTIFICIAL KIDNEY; CELL CULTURE; CONTRAST INDUCED NEPHROPATHY; DIALYSIS; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INTENSIVE CARE; KIDNEY DISEASE; LETHALITY; MORTALITY; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHABDOMYOLYSIS; SUSTAINED LOW EFFICIENCY DAILY DIALYSIS; THROMBOCYTOPENIA; VITAMIN D METABOLISM;

EID: 67650547693     PISSN: 09475362     EISSN: None     Source Type: Journal    
DOI: 10.5414/ibp34094     Document Type: Review

References (33)

1. Bagshaw SM, Berthiaume LR, Delaney A et al. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med. 2008; 36: 610-617. (Pubitemid 351158640)
2. Bellomo R, Cass A, Cole L et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high-dose versus standard-dose hemofiltration in acute renal failure. Blood Purif. 2008; 26: 407-416.
3. Bellomo R, Ronco C, Kellum JA et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004; 8: R204-212.
4. Bonventre JV. Dialysis in acute kidney injury - more is not better.NEngl J Med. 2008; 359: 82-84.
5. Chertow GM, Burdick E, Honour M et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. JAmSoc Nephrol. 2005; 16: 3365-3370. (Pubitemid 46179340)
6. Chertow GM, Levy EM, Hammermeister KE et al. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med. 1998; 104: 343-348. (Pubitemid 28211024)
7. Cruz DN, Perazella MA, Bellomo R et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis. 2006; 48: 361-371. (Pubitemid 44262427)
8. Cruz DN, Perazella MA, Ronco C. The role of extracorporeal blood purification therapies in the prevention of radiocontrast-induced nephropathy. Int J Artif Organs. 2008; 31: 515-524.
9. Ding F, Humes HD. The bioartificial kidney and bioengineered membranes in acute kidney injury. Nephron Exp Nephrol. 2008; 109: e118-122.
10. Fissell WH, Dyke DB, Weitzel WF et al. Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purif. 2002; 20: 55-60. (Pubitemid 34102509)
11. Fissell WH, Lou L, Abrishami S et al. Bioartificial kidney ameliorates gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol. 2003; 14: 454-461. (Pubitemid 36150870)
12. Gabriel DP, Caramori JT, Martim LC et al. High volume peritoneal dialysis vs daily hemodialysis: a randomized, controlled trial in patients with acute kidney injury. Kidney Int. 2008; 108 (Suppl): S87-93.
13. Gritters M, Grooteman MP, Schoorl M et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant. 2006; 21: 153-159. (Pubitemid 43057124)
14. Humes HD, Buffington DA, Lou L et al. Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med. 2003; 31: 2421-2428. (Pubitemid 37281724)
15. Humes HD, Weitzel WF, Bartlett RH et al. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int. 2004; 66: 1578-1588. (Pubitemid 39298393)
16. Hutchison CA, Cockwell P, Reid S et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007; 18: 886-895. (Pubitemid 46434505)
17. Hutchison CA, Harding S, Mead G et al. Serum free-light chain removal by high cut off hemodialysis: optimizing removal and supportive care. Artif Organs. 2008; 32: 910-917.
18. Koster A, Hentschel T, Groman T et al. Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg. 2007; 133: 1376-1377. (Pubitemid 46656385)
19. Lee PT, Chou KJ, Liu CPet al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. Arandomized controlled trial. J Am Coll Cardiol. 2007; 50: 1015-1020. (Pubitemid 47348230)
20. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. Acohort analysis. JAMA. 1996; 275: 1489-1494.
21. Link A, Girndt M, Selejan S et al. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med. 2009; 37: 105-110.
22. Metnitz PG, Krenn CG, Steltzer H et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med. 2002; 30: 2051-2058.
23. Oudemans-van Straaten HM, Bosman RJ, Koopmans M et al. Citrate anticoagulation for continuous veno-venous hemofiltration. Crit Care Med. 2009; 37: 545-552.
24. Overberger P, Pesacreta M, Palevsky MP. Management of renal replacement therapy in acute kidney injury: a survey of practitioner prescribing practices. Clin J Am Soc Nephrol. 2007; 2: 623-630.
25. Palevsky PM. Indications and timing of renal replacement therapy in acute kidney injury. Crit Care Med. 2008; 36 (Suppl 4): S224-228.
26. Palevsky PM, Zhang JH, O'Connor TZ et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008; 359: 7-20. (Pubitemid 351931092)
27. Ricci Z, Ronco C. Dose and efficiency of renal replacement therapy: continuous renal replacement therapy versus intermittent hemodialysis versus slow extended daily dialysis. Crit Care Med. 2008; 36 (Suppl 4): S229-237.
28. Ronco C, Bellomo R, Homel P et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000; 356: 26-30. (Pubitemid 30416991)
29. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002; 346: 305-310. (Pubitemid 34438837)
30. Seabra VF, Balk EM, LiangosOet al. Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis. Am J Kidney Dis. 2008; 52: 272-284. (Pubitemid 351978141)
31. Tumlin J, Wali R, Williams W et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol. 2008; 19: 1034-1040.
32. Uchino S. Choice of therapy and renal recovery. Crit Care Med. 2008; 36 (Suppl 4): S238-242.
33. Uchino S, Bellomo R, Kellum JA et al. Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. Int J Artif Organs. 2007; 30: 281-292. (Pubitemid 46938852)